Lieberman health staffer resigns
Executive Summary
Sen. Joseph Lieberman (D-Conn.) Counsel Chuck Ludlam will leave Capitol Hill in late June to serve as a Peace Corps volunteer in Senegal. Ludlam was involved in developing the "Bioshield" bill enacted in 2004 and Lieberman's version of "Bioshield II" (S 975), introduced on April 28 (1"The Pink Sheet" May 9, 2005, p. 23). Before joining Lieberman's office, Ludlam was the Biotechnology Industry Organization's VP-government affairs...
You may also be interested in...
Hatch/Lieberman “BioShield II” Sets 180-Day Window For “Wild Card” Patents
Manufacturers who enter into biodefense contracts must notify the government within 180 days which patent would be covered by a potential "wild card" extension under the final version of "BioShield II" legislation from Sens. Orrin Hatch (R-Utah), Joe Lieberman (D-Conn.) and Sam Brownback (R-Kan.)
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.